Home > Insider Trading > Filing (0000919574-10-002182)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1124608	Response Genetics Inc	RGDX	In Vitro & In Vivo Diagnostic Substances (2835)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1315309	Partnership Limited Partners Lansdowne	15 Davies Street London W1K 3Ag X0		No	No	Yes	No
1469444	Ltd Fund Master Investment Strategic Uk Lansdowne	C/O Fortis Prime Fund Solutions Fortis House, Park Lane, Spencer Dock Dublin I L2		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, Par Value $0.01 Per Share	Acquisiton	2010-03-05	600,769	$1.31	3,658,676	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock, Par Value $0.01 Per Share	3,658,676	Indirect	See Footnote

Footnotes

These reported securities are held in the account of Lansdowne UK Strategic Investment Master Fund Limited (the "Master Fund"). The Master Fund entered into apurchase agreement with the Issuer as of March 5, 2010 whereby the Master Fund acquired 600,769 shares of common stock from the Issuer in a private transaction(the "Acquisition"). The Master Fund entered into the Acquisition in order to maintain the same percentage of common stock that it beneficially owned prior to theissuance of additional shares of equity securities by the Issuer. Therefore, the percentage of shares beneficially owned by the Master Fund did not change as aresult of the Acquisition.
These reported securities are held in the account of the Master Fund and may be deemed to be beneficially owned by Lansdowne Partners Limited Partnership byvirtue of its role as the investment advisor of the Fund. Lansdowne Partners Limited Partnership disclaims beneficial ownership of the reported securities except tothe extent of its pecuniary interest therein, and this report shall not be deemed an admission that Lansdowne Partners Limited Partnership is the beneficial owner ofthese securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.